REVVITY, INC. RVTY revenue by segment, product and geography
In its fiscal year ending 2025-12-31, REVVITY, INC. reported revenue across 2 business segments; the largest, Life Sciences, was $1.43B, 50.1% of the filed sum (+2.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Life Sciences$1.43B50.1%+2.3% yoy
- Diagnostics$1.42B49.9%+5.1% yoy
Members sum to the consolidated $2.86B for this period.
- Product$2.39B83.7%+2.2% yoy
- Service$466M16.3%+11.8% yoy
Members sum to the consolidated $2.86B for this period.
- Total International$1.73Bshare n/a+4.4% yoy
- Americas$1.26Bshare n/a+2.7% yoy
- United States$1.13Bshare n/a+2.6% yoy
- Other International$1Bshare n/a+7.4% yoy
- Europe$825Mshare n/a+11.1% yoy
- Asia$775Mshare n/a-1.8% yoy
- China$425Mshare n/a-5.5% yoy
- Germany$178Mshare n/a+9.3% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Life Sciences$362M50.9%+6.3% yoy
- Diagnostics$349M49.1%+7.7% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.